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Abstract 
Purpose: Head and neck squamous cell carcinoma (HNSCC), one of the most common 
types of human cancer, show persistent invasion that frequently leads to local recurrence 
and distant lymphatic metastasis.  However, molecular mechanisms associated with 
invasion of HNSCC remain poorly understood.  We identified Interferon-induced 
transmembrane protein 1 (IFITM1) as a candidate gene for promoting the invasion of 
HNSCC by comparing the gene expression profiles between parent and a highly invasive 
clone.  Therefore, we examined the role of IFITM1 in the invasion of HNSCC. 
Experimental Design: IFITM1 expression was examined in HNSCC cell lines and cases 
by RT-PCR and immunohistochemistry.  IFITM1 overexpressing and knockdown cells 
were generated, and the invasiveness of these cells was examined by in vitro invasion 
assay.  Gene expression profiling of HNSCC cells overexpressing IFITM1 versus control 
cells was examined by microarray. 
Results: HNSCC cells expressed IFITM1 mRNA at higher levels, while normal cells did 
not express.  By immunohistochemistry, IFITM1 expression was observed in early 
invasive HNSCC and invasive HNSCC.  Interestingly, IFITM1 was expressed at the 
invasive front of early invasive HNSCC, and higher expression of IFITM1 was found in 
invasive HNSCC.  In fact, IFITM1 overexpression promoted and IFITM1 knockdown 
suppressed the invasion of HNSCC cells in vitro.  Gene expression profiling of HNSCC 
cells overexpressing IFITM1 versus control cells revealed that several genes including 
matrix metalloproteinase were up-regulated in IFITM1 overexpressing cells.   
Conclusion: Our findings suggest that IFITM1 plays an important role for the invasion at 
the early stage of HNSCC progression, and that IFITM1 can be a therapeutic target for 
HNSCC. 
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Introduction 
Head and neck squamous cell carcinoma (HNSCC) is one of the most common types of 
human cancer, with an annual incidence of more than 500,000 cases worldwide (1).  The 
extent of lymph node metastasis is a major determinant in the prognosis of HNSCC.  Like 
most epithelial cancers, HNSCC develops through the accumulation of multiple genetic 
and epigenetic alterations in a multi-step process (2).  Recent molecular studies have 
advanced our understanding of the disease and provided a rationale to develop novel 
strategies for early detection, classification, prevention and treatment.  Attempts to 
identify the genes involved in the metastasis are pivotal for the early prediction of HNSCC 
behavior.  The process of metastasis consists of sequential and selective steps including 
proliferation, induction of angiogenesis, detachment, motility, invasion into circulation, 
aggregation and survival in the circulation, cell arrest in distant capillary beds and 
extravasation into organ parenchyma (2).  We previously established an HNSCC cell line, 
MSCC-1, from lymph node metastasis (3).  Moreover, we isolated a highly invasive clone 
MSCC-Inv1 from MSCC-1 cells by using an in vitro invasion assay device (4).  Then, we 
compared the transcriptional profile of parent cells (MSCC-1) and a highly invasive clone 
(MSCC-Inv1) by microarray analysis in order to identify genes that differ in their expression 
(5).  Several genes were selectively overexpressed in the highly invasive clone.  Among 
these genes, the most highly expressed gene was Periostin, and the second was IFITM1.  
In fact, we demonstrated that Periostin promoted invasion both in vitro and in vivo (5).   
 IFITM1, also known as 9-27 or Leu13, is a member of the interferon-inducible 
transmembrane protein family.  IFITM1 gene product was initially identified as Leu13, a 
leukocyte antigen that is a part of a membrane complex involved in the transduction of 
antiproliferative and homotypic adhesion signals in lymphocytes (6-9).  Moreover, IFITM1 
is a 17-kD membrane protein that was inducible on tumor cell lines by interferon-alpha and 
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usually to a lesser extent, by interferon (10).  However, there have been a few papers of 
IFITM1 in cancer and the role of IFITM1 in cancer is poorly understood.  In the present 
study, therefore, we examined the roles of IFITM1 for HNSCC invasion. 
 
Materials and methods 
Cell culture 
MSCC-1 and MSCC-Inv1 cells were previously established in our laboratory (Kudo et al., 
2003; Kudo et al., 2004).  These cells were maintained in Keratinocyte-SFM (Invitrogen) 
under a condition of 5 % CO2 in air at 37 ˚C.  HNSCC cell lines (HSC2, HSC3, HSC4, Ca9-
22, Ho-1-N-1 and Ho-1-U-1) were provided by Japanese Collection of Research Bioresources 
Cell Bank.  They were maintained in RPMI-1640 (Nissui Pharmaceutical Co., Tokyo, Japan) 
supplemented with 10 % heat-inactivated FBS (Invitrogen) and 100 U/ml penicillin-
streptomycin (Gibco) under conditions of 5 % CO2 in air at 37 ˚C.  Normal oral epithelial cells 
and gingival fibroblasts were obtained from oral mucosa or gingival tissues using standard 
explant techniques (11).  These tissues were obtained from routine dental surgery in the 
Department of Oral Surgery, Hiroshima University Hospital.  Normal oral epithelial cells were 
routinely maintained in Keratinocyte-SFM (GIBCO BRL, Grand Island, NY) and gingival 
fibroblasts were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplement with 
10 % fetal bovine serum.  For growth assay, cells were plated on 24 well plates (Falcon), and 
trypsinized cells counted by Cell Counter (Coulter Z1). 
 
RT-PCR   
Total RNA was isolated from cultures of confluent cells using the RNeasy Mini Kit (Qiagen).  
Preparations were quantified and their purity was determined by standard 
spectrophometric methods.  cDNA was synthesized from 1 μg total RNA according to 
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the ReverTra Dash (Toyobo Biochemicals, Tokyo, Japan).  Primer sequences were listed 
in Table 1A.  Aliquots of total cDNA were amplified with Go Taq® Green Master Mix 
(Promega), and amplifications were performed in a PC701 thermal cycler (Astec, Fukuoka, 
Japan) for 25 (IFITM1 and CD81) or 30 (GAPDH, ßTrcp-1, ßTrcp2, ZNF236, MMP13 and 
MMP12) cycles after an initial 30 sec denaturation at 94 ˚C, annealed for 30 sec at 60 ˚C, 
and extended for 1 min at 72 ˚C in all primers.  The amplification reaction products were 
resolved on 1.5% agarose/TAE gels (Nacalai tesque, Inc., Kyoto, Japan), electrophoresed 
at 100 mV, and visualized by ethidium-bromide staining. 
 
Western blot analysis   
Western blotting was carried out as we described previously (5).  An anti-IFITM1 
polyclonal antibody (Boster Biological Technology. Ltd, Wuhan, China), anti-FLAG 
monoclonal antibody (Sigma) and anti-Cul1 polyclonal antibody (Zymed) were used.  
Thirty ?g of protein was subjected to 10 % polyacrylamide gel electrophoresis followed by 
electroblotting onto a nitrocellulose filter.  For detection of the immunocomplex, the ECL 
western blotting detection system (Amersham) was used. 
 
Tissue samples   
Tissue samples of HNSCC were retrieved from the Surgical Pathology Registry of 
Hiroshima University Hospital, after approval by the Ethical Committee of our institutions.  
Twenty cases of frankly invasive HNSCC, 11 early invasive HNSCC and 10 normal oral 
mucosal tissues were used in this study.  10 % buffered-formalin fixed and paraffin 
embedded tissues were used for immunohistochemical examination.  The histological 
grade and stage of tumor were classified according to the criteria of the Japan Society for 
Head and Neck Cancer.   
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Immunohistochemical staining   
Immunohistochemical detection of IFITM1 in HNSCC cases was performed on 4.5 μm 
sections mounted on silicon-coated glass slides, using a streptavidin-biotin peroxidase 
technique as described previously (12).   
 
Generation of IFITM1-overexpressing HNSCC cells   
Human IFITM1 cDNA was isolated from the cDNA by RT–PCR using sense and antisense 
primers.  Human IFITM1 cDNA was then subcloned by insertion into the EcoRI/BamHI 
restriction site of pBICEP-CMV-2 (Sigma).  The IFITM1-pBICEP-CMV-2 plasmid or the 
vector alone was introduced into Ca9-22 cells, and the stable clones were obtained by 
G418 selection (500 μg/ml, Gibco) in the culture medium.  We obtained pool and 4 stable 
clones.  Cell transfection was performed using FuGENE 6 HD (Roche) according to the 
manufacture’s instruction.   
 
In vitro invasion assay   
In vitro invasion assay was performed as described previously (4,13).  Briefly, invasion was 
measured by use of a 24 well cell culture insert with 8 μm pores (3097, Falcon, Becton 
Dickinson, Franklin Lakes, NJ).  The filter was coated with 50 μg of Matrigel (Becton 
Dickinson), which was reconstituted basement membrane substance.  The lower 
compartment contained 0.5 ml of serum-free medium.  After trypsinization, 1.5 x 105 cells 
were resuspended in 100 μl of serum-free medium and placed in the upper compartment of 
the cell culture insert for 24 hours.  To examine the invasiveness, penetrated cells onto the 
lower side of the filter were fixed with formalin and stained with hematoxylin.  We assayed 
3 times. 
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Wound healing assay  
For the wounding healing experiment, cells were seeded on 6 well plates and cells were 
allowed to grow to complete confluence.  Subsequently, a plastic pipette tip was used to 
scratch the cell monolayer to create a cleared area, and the wounded cell layer was washed 
with fresh medium to remove loose cells.  Immediately following scratch wounding (0 h) 
and after incubation of cells at 37 °C for 24 h, phase-contrast images (10x field) of the 
wound healing process were photographed digitally with an inverted microscope.  The 
distance of the wound areas were measured on the images, set at 100% for 0 h, and the 
mean percentage of the total distances of the wound areas was calculated. 
 
RNA interference experiments   
shRNAs were designed based on the prediction of publicly available prediction programs 
(14), which are summarized in Table 1B.  shRNAs were cloned into the transient micro-
RNA expression vector pcDNA6.2-GW/emGFP/miR (Invitrogen), which co-expresses the 
shRNA surrounded by miR-155–flanking sequences together with emGFP.  Logarithmically 
growing Ca9-22 and HSC2 cells were seeded at a density of 105cells/6cm dish and were 
transfected.  After 48h of transfection, we treated blasticidin for 10 days.  After selection, 
we obtained the stably shRNA expressing cells.  si-miR-neg, provided by Invitrogen, has 
an insert that can form a hairpin structure that is processed into mature miRNA, but it is 
predicted not to target any known vertebrate gene (according to Invitrogen).  Transfection 
efficiency was checked by GFP expression under UV microscopy and by RT-PCR. 
 For knockdown of ß-Trcp, we used the siRNA oligos.  The siRNA oligos used for 
both ß-Trcp1 and ß-Trcp2 silencing were 21 bp synthetic molecules (Dharmacon Research) 
corresponding to nt 407-427 of human ß-Trcp1 and 161-181 of human ß-Trcp2 (AB033279) 
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(15).  A 21 nt siRNA duplex corresponding to a non-relevant F-Box protein (Fbp) gene was 
used as a control.  Logarithmically growing Ca9-22 cells were seeded at a density of 
105cells/6cm dish and transfected with oligos twice (at 24 and 48 hr after replating) using 
Oligofectamine (Invitrogen) as described (16).  Forty-eight hours after the last transfection, 
lysates were prepared and analyzed by SDS-PAGE and immunobloting. 
 
Gene array analysis                                                          
The human focus array using the system containing 50000 genes probes was used for 
comparing the transcriptional profiles between IFITM1 overexpressing Ca9-22 cells and 
control Ca9-22 cells.  This array contains a broad range of genes derived from publicly 
available, well-annotated mRNA sequences.  Total RNA was isolated from cultures of 
confluent cells using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s 
instructions.  Preparations were quantified and their purity was determined by standard 
spectrophometric methods.  Data were expressed as the average differences between 
the perfect match and mismatch probes for the IFITM1 gene.  
 
Results 
IFITM1 overexpression is frequently found in HNSCC.  
We previously identified IFITM1 as an invasion-promoting factor of HNSCC by comparing 
the transcriptional profile of parent HNSCC cells (MSCC-1) and a highly invasive clone 
(MSCC-Inv1) (5).  The finding of higher expression of IFITM1 in the highly invasive clone 
than the parent cells was confirmed by RT-PCR (Fig. 1A).  Next, we examined the IFITM1 
mRNA in 6 HNSCC cell lines, normal oral epithelial cells and normal gingival fibroblasts.  
IFITM1 mRNA expression was observed in all HNSCC cell lines, but not in normal 
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epithelial cells and fibroblasts (Fig. 1B).  IFITM1 protein expression was examined by 
Western blot analysis in HNSCC cells, and anti-IFITM1 antibody recognized IFITM1 
protein (Fig. 1C).  By using this antibody, we examined the expression of IFITM1 by 
immunohistochemistry to know the localization of IFITM1 in HNSCC.  Twenty cases of 
frankly invasive HNSCC, 11 early invasive HNSCC and 10 normal oral mucosal tissues 
were used in this study.  In normal oral epithelium, only basal cells slightly expressed 
IFITM1 in their cytoplasm and membrane (Fig. 1D).  In early invasive HNSCC, 
surrounding cells in cancer nests of invasive front expressed IFITM1 at higher levels in 
comparison with basal cells in normal epithelium (Fig. 1D).  In frankly invasive HNSCC, 
cancer cells expressed IFITM1 at higher levels in their cytoplasm and membrane (Fig. 1D).  
As all cancer cases expressed IFITM1 at higher levels, we could not compare with clinico-
pathological findings including histological differentiation and metastasis.  Thus, high 
expression of IFITM1 was focally observed in invasive front of early invasive HNSCC and 
diffusely observed in invasive HNSCC.  This finding suggests that IFITM1 may be 
involved in the invasion at the early stage of HNSCC progression.  For further evaluation 
of IFITM1 expression in patients with HNSCC, we compared the expression in a previously 
published microarray dataset of 41 HNSCC patients and 13 normal controls (17).  Similar 
to our data, IFITM1 was expressed at higher levels in HNSCC tissues, in comparison with 
normal oral mucosal tissues (Fig. 1E). 
 
IFITM1 is involved in the invasion of HNSCC cells.   
To demonstrate the involvement of IFITM1 in the invasion of HNSCC, we generated the 
IFITM1 overexpressing cells.  We transfected IFITM1 into Ca9-22 cells that showed low 
expression of IFITM1.  Then, we obtained 3 stable clones of IFITM1 expressing cells (Fig. 
2A).  IFITM1 overexpression did not change the cell proliferation (Fig. 2B).  We 
 
                                                                 Hatano et al., 11 
compared the invasiveness between control and IFITM1 overexpressing HNSCC cells.  
By in vitro invasion assay, IFITM1 overexpression enhanced the invasion (Fig. 2C).  
Moreover, IFITM1 overexpression enhanced the migration by wound healing assay (Fig. 
2D).  To confirm the IFITM1-mediated invasion of HNSCC cells, we examined the 
knockdown of IFITM1 by using short hairpin RNAs (shRNAs) in HSC2 cells with high 
expression of IFITM1.  We designed three different short hairpin RNAs (#1, #2 and #3) 
and transfected them into HSC2 cells.  All shRNAs reduced the IFITM1 expression (Fig. 
3A).  IFITM1 shRNAs did not influence the cell proliferation (Fig. 3B), but IFITM1 shRNAs 
remarkably inhibited the invasion of HNSCC cells (Fig. 3C).   
 
CD81 is involved in the invasion of HNSCC cells  
CD81 is a widely expressed cell-surface protein involved in an astonishing variety of 
biologic responses (18).  CD81 associates on the surface of B cells in a molecular 
complex that includes the B-cell-specific molecules CD19 and CD21 and Leu-13/IFITM1 
(18).  As we thought that CD81 may be involved in IFITM1 mediated invasion of HNSCC 
cells, we examined the correlation between CD81 and IFITM1 expression in HNSCC cells.  
First, we examined the expression of CD81 mRNA in HNSCC cell lines and normal cells.  
In similar to IFITM1 expression, CD81 expression was observed only in HNSCC cells, but 
not in normal oral epithelial cells and gingival fibroblasts (Fig. 4A).  To check the 
correlation between IFITM1 and CD81, we examined the CD81 expression in IFITM1 
overexpressing and IFITM1 knockdown cells.  Although IFITM1 overexpression 
enhanced CD81 expression, IFITM1 knockdown did not affect CD81 expression (Fig. 4B).  
To know the role of CD81 for the invasion of HNSCC cells, we examined the knockdown 
of CD81 in HSC2 cells by using shRNA.  We designed three different short hairpin RNAs 
(#1, #2 and #3) and transfected them into HSC2 cells.  All shRNAs reduced CD81 
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expression, but did not influence on IFITM1 expression (Fig. 5A).  In similar to the 
phenotype of IFITM1 knockdown cells, CD81 knockdown remarkably inhibited the invasion 
of HNSCC cells (Fig. 5B).  Moreover, we transfected three different CD81 shRNA into the 
IFITM1 overexpressing HNSCC cells (Fig. 5C).  CD81 knockdown inhibited the IFITM1 
enhanced invasion of HNSCC cells, indicating that CD81 may be involved in the invasion 
of HNSCC cells (Fig. 5C). 
 Recent studies have shown that during embryogenesis, BMP4 and Wnt/ß-catenin 
signaling were able to control the level of expression of IFITM1, and that IFITM1 is induced 
by activation of the Wnt/ß-catenin signaling during intestinal tumorigenesis (19,20).  
Therefore, we examined whether overexpression of IFITM1 in HNSCC cells is induced by 
activation of the Wnt/ß-catenin signaling.  ß-Trcp siRNA treatment induced ß-catenin 
accumulation, indicating the activation of the Wnt/ß-catenin signaling (Fig. 5D).  However, 
IFITM1 was not up-regulated in ß-Trcp siRNA treated HNSCC cells (Fig. 5D). 
 
IFITM1 overexpression induces up-regulation of MMP. 
To know the mechanism of IFITM1 for the invasion of HNSCC cells, we compared the 
gene transcriptional profiles of control and IFITM1 overexpressing HNSCC cells.  By 
microarray analysis, several genes were selectively overexpressed in IFITM1 
overexpressing HNSCC cells (Table 2).  Among these genes, ZNF236 was the most 
highly expressed gene.  ZNF236, a novel Kruppel-like zinc-finger gene was initially 
identified by its glucose-regulated expression in human mesangial cells using mRNA 
differential display (21).  In addition, MMP13 and MMP12 were up-regulated in IFITM1 
overexpressing HNSCC cells.  Certain aspects of MMP involvement in tumor metastasis 
such as tumor-induced angiogenesis, tumor invasion, and establishment of metastatic foci 
at the secondary site, have received extensive attention that resulted in an overwhelming 
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amount of experimental and observational data in favor of critical roles of MMPs in these 
processes (22).  Highly expression of ZNF236, MMP13 and MMP12 in IFITM1 
overexpressing HNSCC cells was confirmed by RT-PCR (Fig. 5E). 
 
Discussion 
We previously identified several genes, which encode secretary or cell surface proteins 
implicated in invasion, cell adhesion, angiogenesis and growth factor as a candidate gene 
for the invasion of HNSCC by comparing the gene expression profiles between parent 
HNSCC cells and a highly invasive clone using microarray analysis (5).  IFITM1 was the 
second of overexpressed genes in highly invasive clones and we considered as a novel 
candidate gene for HNSCC invasion.  As we expected, IFITM1 overexpression promoted 
the invasion and migration of HNSCC cells in vitro (Fig. 2).  These findings are consistent 
with the recent report that IFITM1 modulates the invasiveness of gastric cancer cells (23).  
We also found that high expression of IFITM1 was focally observed in invasive front of 
early invasive HNSCC and diffusely observed in invasive HNSCC by 
immunohistochemical analysis, suggesting that IFITM1 may be involved in the invasion at 
the early stage of HNSCC progression.  This observation is consistent with recent report 
that expression of several members of the IFITM family was up-regulated in early and late 
intestinal neoplasms by using different mouse models of Apc inactivation and human colon 
tumor samples, and that up-regulation of the IFITM genes seems to be an early event in ß-
catenin intestinal tumorigenesis (20).  We suggest that IFITM1 may be involved in the 
initial step of invasion such as the degradation of the basement membrane and the 
interstitial extracellular matrix, which results in cellular infiltration into the adjacent tissue.  
In our microarray analysis, we identified Periostin as the most highly expressed gene in 
highly invasive clones (5).  In fact, we demonstrated that Periostin dramatically enhanced 
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invasion, anchorage independent growth both in vitro and in vivo, and that Periostin 
overexpression was well correlated with poorly differentiation and metastasis in HNSCC 
cases by immunohistochemistry (5).  We suggested that Periostin overexpression might 
be a late event such as the aggressive invasion into surrounding tissues, invasion into 
circulation, and extravasation into organ parenchyma in HNSCC progression.  Overall 
IFITM1 and Periostin can be a marker for predicting the invasion of HNSCC at the early 
and late stage of HNSCC progression, respectively. 
To know the mechanism of IFITM1 for invasion of HNSCC cells, we compared the 
gene expression profiles between control and IFITM1 overexpressing HNSCC cells.  
IFITM1 overexpression enhanced MMP12 and MMP13 expression in HNSCC cells (Fig. 
5E and Table 1), suggesting that IFITM1 enhanced invasion of HNSCC cells through the 
activation of certain type of MMP.  Previous studies demonstrated that IFITM1 associates 
with CD81 and make a complex with CD19 and CD21 (18).  In addition, it has been 
reported that constitutive up-regulation of CD81 is associated with an increased growth 
rate and tumor progression in a mouse model of skin tumor (24).  Therefore, we asked 
whether CD81 was involved in the IFITM1 induced invasion of HNSCC cells or not.  In 
similar to IFITM1 expression, CD81 expression was observed in HNSCC cells, but not in 
normal cells (Fig. 4A).  Interestingly, IFITM1 overexpression enhanced CD81 expression 
(Fig. 4B) and knockdown of CD81 inhibited the invasion of HNSCC cells in similar to 
IFITM1 knockdown (Fig. 5B).  Moreover, CD81 knockdown abolished IFITM1 induced 
invasion of HNSCC cells (Fig. 5C).  Although these findings suggest that CD81 may be 
involved in the invasion of HNSCC, the association between IFITM1 and CD81 for the 
invasion of HNSCC cells is still unclear.  As CD81 is associated with integrins (?6ß1 and 
?3ß1) in HeLa cells (25), CD81 induced invasion may be associate with certain type of 
integrins.  It is also known that CD81 is considered a putative receptor for hepatitis C 
 
                                                                 Hatano et al., 15 
virus (26).  Therefore, this finding raises the possibility that unknown ligand may bind to 
CD81 and may be involved in CD81 induced invasion.  To demonstrate the detailed 
molecular mechanisms of IFITM1 and CD81 for cancer invasion, further studies will be 
required. 
In the present study, highly expression of IFITM1 was observed in all HNSCC 
cancer cell lines and invasive HNSCC cancer cases.  Up-regulation of IFITM1 was 
observed in colon, rectal, stomach and lung cancers by large-scale analysis of IFITM 
expression (22).  Therefore, up-regulation of IFITM1 may be a common event in the 
progression of various cancers.  Recent studies have shown that during embryogenesis, 
BMP4 and Wnt/ß-catenin signaling were able to control the level of expression of IFITM1, 
and that IFITM1 is induced after activation of the Wnt/ß-catenin signaling during intestinal 
tumorigenesis (19,20).  However, IFITM1 was not up-regulated by activation of the Wnt/ß-
catenin signaling in HNSCC cells (Fig. 5D).  To clarify the mechanism of up-regulation of 
IFITM1 will required further studies.  In conclusion, our studies have revealed a critical 
role of IFITM1 for the invasion at the early stage of HNSCC progression.  These findings 
provide new and important information on the progression of HNSCC and suggest that 
IFITM1 could be used as a novel molecular target for therapy of HNSCC patients. 
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Figure legends 
Fig. 1. Overexpression of IFITM1 in HNSCC.  (A) Confirmation of higher expression of 
IFITM1 mRNA in the highly invasive clone by RT-PCR.  (B) Expression of IFITM1 mRNA 
in 6 HNSCC cell lines, normal oral epithelial cells and gingival fibroblasts.  Expression of 
IFITM1 mRNA was performed by RT-PCR.  (C) Expression of IFITM1 protein in 6 
HNSCC cell lines by Western blot analysis.  Cul1 expression was used as a loading 
control.  (D) Expression of IFITM1 was examined by immunohistochemistry in normal oral 
mucosae (Normal, x40), early invasive HNSCC (early invasive SCC, x40) and invasive 
HNSCC (SCC, x40).  Representative cases of IFITM1 expression were shown.  (E) Total 
RNA from 41 primary HNSCC and 13 normal tissues was labeled and hybridized to 
Affymetrix U133A Gene Chips as previously reported (17).  Graph shows the signal 
intensity of IFITM1 in 41 HNSCC and 13 normal tissues in microarray analysis in normal 
and HNSCC tissues.  The average of signal intensity of IFITM1 is shown at the bottom of 
the graph.   
 
Fig. 2. IFITM1 promotes the invasion of HNSCC cells.  (A) Generation of IFITM1 
overexpressing cells.  Ca9-22 cells were engineered to overexpressing IFITM1 by 
transfection with pBICEP-CMV-2-IFITM1.  We obtained 3 stable clones of IFITM1 
overexpressing cells.  Ectopic expression of IFITM1 was examined by immunobloting with 
anti-FLAG antibody.  The whole lysates from all samples were blotted with Cul1 for a 
loading control.  (B) Cell proliferation of IFITM1 overexpressing HNSCC cells.  Cells were 
plated on 24 well plates, and trypsinized cells were counted by Cell Counter at 0 and 4 day.  
We defined 1 as a number of cells at 0 day and calculated the fold change of number of 
cells at 4 day.  (C) Invasion of IFITM1 overexpressing HNSCC cells.  The invasiveness of 
the cells was determined by in vitro invasion assay.  1.5 x 105 cells were placed in the 
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upper compartment of the cell culture insert for 24 h.  To examine the invasiveness, 
penetrated cells onto the lower side of the filter were fixed with formalin and stained with 
hematoxylin.  We assayed 3 times.  (D) Migration of IFITM1 overexpressing HNSCC cells.  
We used one of stable clones for wound healing assay.  Migration of the cells was 
determined by wound healing assay.  At 24h after scratching the cells, phase-contrast 
images (10x field) of the wound healing process were photographed digitally with an 
inverted microscope.  The distance of the wound areas were measured on the images, set 
at 100% for 0 h, and the mean percentage of the total distances of the wound areas was 
calculated. 
 
Fig. 3. IFITM1 shRNA inhibited the invasion of HNSCC cells.  (A) Three different IFITM1 
shRNAs were stably transfected in HSC2 cells.  After transfection, we treated blastidin for 
selection.  IFITM1 mRNA expression is examined by RT-PCR.  GAPDH expression was 
used as a loading control.  (B) Cell proliferation of IFITM1 shRNA transfected cells.  
Cells were plated on 24 well plates and trypsinized cells were counted by Cell Counter at 0 
and 4 day.  We defined 1 as a number of cells at 0 day and calculated the fold change of 
number of cells at 4 day.  (C) Invasion of IFITM1 shRNA transfected cells.  The 
invasiveness of the cells was determined by in vitro invasion assay.  1.5 x 105 cells were 
placed in the upper compartment of the cell culture insert for 24 h.  To examine the 
invasiveness, penetrated cells onto the lower side of the filter were fixed with formalin and 
stained with hematoxylin.  We assayed 3 times.   
 
Fig. 4. Correlation between IFITM1 and CD81 in HNSCC cells.  (A) Expression of CD81 
mRNA in 6 HNSCC cell lines, normal oral epithelial cells and gingival fibroblasts.  
Expression of CD81 mRNA was performed by RT-PCR.  The picture of IFITM1 and 
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GAPDH mRNA expression is same as Figure 1b.  (B) CD81 expression was examined in 
IFITM1 overexpressing and IFITM1 knockdown cells by RT-PCR.  The picture of IFITM1 
and GAPDH expression in IFITM1 overexpressing and IFITM1 knockdown cells is same 
as Figure 2a and 3a, respectively.  CD81 expression in stable clones of IFITM1 
overexpressing cells is shown in upper panel and CD81 expression in IFITM1 shRNAs 
treated cells is shown in lower panel.   
 
Fig. 5. CD81 is involved in the invasion of HNSCC cells.  (A) Three different CD81 
shRNAs were stably transfected in HSC2 cells.  After transfection, we treated blasticidin 
for selection.  CD81 and IFITM1 mRNA expression is examined by RT-PCR.  GAPDH 
expression was used as a loading control.  (B) Cell proliferation of CD81 shRNA treated 
cells (upper panel).  Cells were plated on 24 well plates and trypsinized cells were 
counted by Cell Counter at 0 and 4 day.  We defined 1 as a number of cells at 0 day and 
calculated the fold change of number of cells at 4 day.  Invasion of CD81 shRNA treated 
cells (lower panel).  The invasiveness of the cells was determined by in vitro invasion 
assay.  1.5 x 105 cells were placed in the upper compartment of the cell culture insert for 
24 h.  To examine the invasiveness, penetrated cells onto the lower side of the filter were 
fixed with formalin and stained with hematoxylin.  We assayed 3 times.  (C) We 
examined the co-transfection of CD81 shRNA into IFITM1 transfected HNSCC cells.  
Three different CD81 shRNAs (#1, 2 and 3) were transiently transfected into IFITM1 
overexpressing Ca9-22 cells.  IFITM1 and CD81 expression was examined by RT-PCR 
(upper panel).  GAPDH was used as a control.  The invasiveness of the cells was 
determined by in vitro invasion assay (lower panel).  1.5 x 105 cells were placed in the 
upper compartment of the cell culture insert for 36 h.  To examine the invasiveness, 
penetrated cells onto the lower side of the filter were fixed with formalin and stained with 
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hematoxylin.  We assayed 3 times.  (D) IFITM1 is not induced by Wnt/ß-catenin 
signaling pathway.  We treated ß-Trcp1/2 siRNA in HNSCC cells.  A 21 nt duplex 
corresponding to a non-relevant Fbp gene was used as a control.  ß-Trcp1/2 siRNA 
induced down-regulation of ß-Trcp1 and ß-Trcp2 mRNA and accumulation of ß-catenin 
protein.  In this ß-Trcp1/2 siRNA treated cells, IFITM1 mRNA was examined by RT-PCR.  
GAPDH was used as a control for RT-PCR.  Cul1 was used as a loading control for 
Western blot analysis.  (E) Gene expression profiles of control and IFITM1 
overexpressing HNSCC cells.  ZNF236, MMP13 and MMP12 were up-regulated in 
IFITM1 overexpressing cells (Table 1).  We confirmed the expression of ZNF236, MMP13 
and MMP12 mRNA in IFITM1 HNSCC overexpressing cells by RT-PCR.  GAPDH 
expression was used as a loading control. 
 
A. Oligonucleotide primer sequences utilized in the RT-PCR
RT-PCR primer set Sequence Product length (bp)
IFITM1 F 5’-atgtcgtctggtccctgttc-3’ 300
R 5’-gtcatgaggatgcccagaat-3’
CD81 F 5’-agatcgccaaggatgtgaag-3’ 213
R 5’-cctccttgaagaggttgctg-3’
GAPDH F 5’-tccaccaccctgttgctgta-3’ 450
R 5’-accacagtccatgccatcac-3’
ßTrcp-1 F 5’-aacggaaactctcagcaagc-3’ 240
R 5’-tggcatccaggtatgacaga-3’
ßTrcp-2 F 5’-aaaccagcctggaatgtttg-3’ 197
R 5’-cagtccattgctgaagcgta-3’
ZNF236 F 5’-agctcactcaaaggcggtaa-3’ 201
R 5’-tatagtcctgtcggggttcg-3’
MMP13 F 5’-ttgagctggactcattgtcg-3’ 171
R 5’-ggagcctctcagtcatggag-3’
MMP12 F 5’-acacatttcgcctctctgct-3’ 192
R 5’-ccttcagccagaagaacctg-3’
shIFITM1
#1 F 5’-TGCTGTTCAGTTTCTCAGAAGTGTGTGTTTTGGCCACTGACTGACACACACTTGAGAAACTGAA-3’
R 5’-CCTGTTCAGTTTCTCAAGTGTGTGTCAGTCAGTGGCCAAAACACACACTTCTGAGAAACTGAAC-3’
#2 F 5’-TGCTGACCAGTGACAGGATGAATCCAGTTTTGGCCACTGACTGACTGGATTCACTGTCACTGGT-3’
R 5’-CCTGACCAGTGACAGTGAATCCAGTCAGTCAGTGGCCAAAACTGGATTCATCCTGTCACTGGTC-3’
#3 R 5’-TGCTGTAATATGGTAGACTGTCACAGGTTTTGGCCACTGACTGACCTGTGACACTACCATATTA-3’
R 5’-CCTGTAATATGGTAGTGTCACAGGTCAGTCAGTGGCCAAAACCTGTGACAGTCTACCATATTAC-3’
shCD81
#1 F 5’-TGCTGAGATACAGGAGGTTGGTGGTCGTTTTGGCCACTGACTGACGACCACCACTCCTGTATCT-3’
R 5’-CCTGAGATACAGGAGTGGTGGTCGTCAGTCAGTGGCCAAAACGACCACCAACCTCCTGTATCTC-3’
#2 F 5’-TGCTGCATACACGCCACCTACATGTGGTTTTGGCCACTGACTGACCACATGTATGGCGTGTATG-3’
R 5’-CCTGCATACACGCCATACATGTGGTCAGTCAGTGGCCAAAACCACATGTAGGTGGCGTGTATGC-3’
#3 R 5’-TGCTGTTGTGATTACAGTTGAAGGCGGTTTTGGCCACTGACTGACCGCCTTCATGTAATCACAA-3’
R 5’-CCTGTTGTGATTACATGAAGGCGGTCAGTCAGTGGCCAAAACCGCCTTCAACTGTAATCACAAC-3’
B. Oligonucleotide sequences utilized for siRNA
Table 2. List of genes up-regulated by IFITM1 (over 6-fold) in Ca9-22 cells 
Ratio(IFITM
1/Control)
Control
Normalized
IFITM1
Normalized
Genbank Common Description
65.7 0.052373156 3.438695 AK000847 ZNF236 Zinc finger protein 236
23.5 0.040916532 0.95997965 AA053711 EDIL3 EGF-like repeats and discoidin I-like domains 3
19.1 0.29541734 5.6548567 NM_002427 MMP13 Matrix metallopeptidase 13 (collagenase 3)
19.1 0.02700491 0.5164415 AI681013 PRDM2 PR domain containing 2, with ZNF domain
12.5 0.039279867 0.490441 NM_024722 ACBD4 Acyl-Coenzyme A binding domain containing 4
10.1 0.049918167 0.50318635 U50748 LEPR Leptin receptor
9.6 0.06628478 0.6377772 D49958 GPM6A Glycoprotein M6A
8.7 0.06382978 0.556207 AF230398 TRIM23 Tripartite motif-containing 23
8.2 0.18903437 1.5421872 NM_002426 MMP12 Matrix metallopeptidase 12 (macrophage elastase)
7.5 0.063011445 0.47004843 AK026191 DDAH2 Dimethylarginine dimethylaminohydrolase 2
7.3 0.7765958 5.682895 NM_005410 SEPP1 Selenoprotein P, plasma, 1
7.0 0.106382966 0.7427989 NM_004585 RARRES3 Retinoic acid receptor responder (tazarotene induced) 3
6.9 0.06873976 0.47667605 AF196478 ANXA10 Annexin A10
6.8 0.2119476 1.4453225 AF096296 CCL26 Chemokine (C-C motif) ligand 26
6.6 0.08428806 0.55365795 AL034410 PCNAP proliferating cell nuclear antigen pseudogene
6.6 0.091653034 0.60056084 BF939489 GPM6A Glycoprotein M6A
6.5 0.117839605 0.7687994 AV747166 PARP11 Poly (ADP-ribose) polymerase family, member 11
6.3 0.29214403 1.8307419 AL541302 SERPINE2 Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor
type 1), member 2
6.0 0.07774141 0.46902883 AL037998 CDNA FLJ30740 fis, clone FEBRA2000319





